Functional profiling of live melanoma samples using a novel automated platform

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Targeted therapy for melanoma relies on understanding drug effects on specific pathways.
• Assessing drug response in live patient samples is crucial for personalized medicine.

Purpose of the Study:

• To evaluate a novel automated platform for deriving functional pharmacodynamic profiles from live human melanoma samples.
• To determine if these profiles are relevant for targeted therapy assessment.

Main Methods:

• Utilized an automated fluidics platform to expose melanoma cell lines and fine needle aspiration (FNA) biopsy samples to a BRAF inhibitor (PLX-4720).
• Measured phosphoprotein p-ERK levels in the mitogen-activated protein kinase (MAPK) pathway using a bead-based immunoassay.
• Analyzed ex vivo samples from melanoma cell lines, murine xenografts, and patient biopsies.

Main Results:

• Sensitive melanoma cell lines showed MAPK pathway suppression, while resistant lines maintained pathway activity.
• Ex vivo analysis of FNA samples from xenografts mirrored cell line responses.
• Patient FNA samples yielded distinct functional profiles (suppression, reactivation, stimulation) correlating with BRAF mutation status and clinical response.

Conclusions:

• The automated platform reproducibly determines ex vivo pharmacodynamic effects of BRAF inhibitors on the MAPK pathway in live melanoma samples.
• This approach holds potential for preclinical/clinical drug development and predicting patient response to targeted therapies.